The ASH/ASCO clinical guidelines on the use of erythropoietin

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 3 SPEC. ISS., 2005, Pages 433-438

  Lichtin, Alan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ASH ASCO; Erythropoietin; Evidence based medicine

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ANEMIA; BLOOD TRANSFUSION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; HUMAN; MYELODYSPLASIA; MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 15844377604     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.020     Document Type: Review

References (8)

1. J.D. Rizzo A.E. Lichtin S.H. Woolf et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood 100 2002 2303-2320
2. A. Lichtin Idiopathic thrombocytopenic purpura: Guidance amid uncertainty Cleve Clin J Med 65 1998 510-514
3. R.T. Silver S.H. Woolf R. Hehlmann et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology Blood 94 1999 1517-1536
4. M.D. Swartz K. Robinson T. Davy G. Politoski The role of patients in the implementation of the National Kidney Foundation-Dialysis Outcomes Quality Initiative Adv Ren Replace Ther 6 1999 52-58
5. J.L. Gabrilove C.S. Cleeland R.B. Livingston et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2001 2875-2882
6. R.N. Greenwood C. Ronco F. Gastaldon et al. Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance Kidney Int Suppl 2003 S78-S86
7. T.J. Littlewood E. Bajetta J.W. Nortier et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865-2874
8. Aronson N, Seidenfeld J, Piper M, Flamm RC & Hasselblad V. Use of Erythropoietin in Oncology. Evidence Report/Technology Assessment No. 30. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290-97-0015. AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality; June 2001. http://www.ahrq.gov/. 2001. Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2101 East Jefferson Street, Rockville, MD 20852. Ref Type: Electronic Citation.